Frazier Life Sciences Management L.P. Sells 200,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Frazier Life Sciences Management L.P. reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 20.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 788,460 shares of the company's stock after selling 200,000 shares during the quarter. Krystal Biotech makes up about 5.1% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 4th biggest holding. Frazier Life Sciences Management L.P. owned about 2.74% of Krystal Biotech worth $123,520,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE increased its stake in shares of Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after buying an additional 82 shares during the period. Summit Investment Advisors Inc. boosted its holdings in Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after acquiring an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after acquiring an additional 121 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Krystal Biotech by 1.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after purchasing an additional 121 shares during the period. Finally, Perigon Wealth Management LLC raised its holdings in Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock worth $1,200,000 after purchasing an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS traded down $0.24 during trading on Monday, hitting $125.05. The company had a trading volume of 298,645 shares, compared to its average volume of 308,069. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of 41.82 and a beta of 0.79. The company has a fifty day simple moving average of $161.34 and a two-hundred day simple moving average of $166.79. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). The firm had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This represents a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on KRYS shares. HC Wainwright reiterated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, May 6th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital restated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 target price on the stock. Finally, Citigroup lowered their price target on shares of Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating for the company in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $211.13.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).